Retrospective study assesses dexmedetomidine during pediatric respiratory support

Dexmedetomidine appeared feasible and generally well tolerated as a sedative adjunct for children receiving non-invasive respiratory support in a single-center retrospective study of 113 patients treated at the pediatric intensive care unit of Batman Training and Research Hospital. Of the 113 children, 111, or 98.2%, completed non-invasive respiratory support without escalation to invasive ventilation. Most of the cohort was treated for moderate to severe acute respiratory failure.

The findings describe the experience of this hospitalized cohort and do not establish that dexmedetomidine caused the observed outcomes or was safer or more effective than another sedative. The analysis included patients admitted between June 1 and December 30, 2022, who received dexmedetomidine while receiving non-invasive respiratory support through either continuous positive airway pressure or high-flow nasal cannula. High-flow oxygen therapy was delivered through a nasal cannula, and continuous positive airway pressure was delivered with a nasal mask.

Dexmedetomidine was administered by infusion at 0.1–0.6 micrograms per kilogram per hour without a loading dose. The study used descriptive statistics and examined variables including age, dexmedetomidine dose, adverse effects, sex, heart rate and respiratory rate. Because the investigation was retrospective and did not include a randomized comparison group, it cannot separate the effects of dexmedetomidine from those associated with respiratory support, changes in illness or other aspects of clinical care.

The cohort included 46% females and 54% males. Patients aged 1–12 months accounted for 55.8% of the group, those aged 13–36 months represented 34.5%, and 9.72% were older than 36 months. Non-invasive respiratory support is frequently used in pediatric patients with moderate to severe acute respiratory failure, but non-compliance can reduce treatment success.

Dexmedetomidine is widely used in adults for its sedative and anxiolytic properties, although its use in pediatric populations has been more limited. The research therefore focused on documenting the clinical feasibility, physiological trends and adverse events associated with its use alongside non-invasive support, rather than directly comparing it with a control treatment. Following initiation of combined non-invasive respiratory support and dexmedetomidine therapy, researchers observed statistically significant reductions in respiratory rate and heart rate, with p-values below 0.001 for both measures.

These were observed changes during treatment, not evidence of a causal effect or a prespecified comparison between groups. The respiratory rate and heart rate findings also applied to the overall cohort, which comprised patients treated for acute respiratory failure and a smaller post-extubation group. Documented adverse effects occurred in five of the 113 children: bradycardia in two, elevated liver enzyme levels in two and hypotension in one.

No adverse events were reported in the remaining 108 patients. The source did not classify these events as serious adverse events, so their frequency should not be interpreted as a formal serious-adverse-event rate. In the stratified analysis, 100 of 102 children, or 98%, in the primary non-invasive support subgroup completed treatment without escalation to invasive ventilation; that subgroup was intended to prevent intubation.

All 11 children in the post-extubation subgroup, intended to prevent re-intubation, also completed non-invasive support without escalation. The post-extubation estimate is based on a particularly small group and therefore has greater uncertainty than the overall cohort result. Overall, the study supports the limited conclusion that dexmedetomidine monotherapy can be administered feasibly in a pediatric intensive care setting alongside non-invasive respiratory support, with lower heart and respiratory rates observed and only a small number of patients experiencing documented adverse effects.

The descriptive results do not show that dexmedetomidine prevents intubation or re-intubation, improves survival, or offers advantages over alternative sedatives. The authors called for prospective comparative trials to investigate the safety and effectiveness of the approach. Until such evidence is available, the reported success rate should be viewed as an observation from one retrospective cohort rather than a treatment-effect estimate.

Subject of Research: Retrospective evaluation of dexmedetomidine sedation during pediatric non-invasive respiratory support

Article Title: Safety and feasibility of dexmedetomidine for sedation in pediatric patients receiving non-invasive respiratory support: a descriptive study

Article References: Yavuz, S., & Avci, A. (2026). Safety and feasibility of dexmedetomidine for sedation in pediatric patients receiving non-invasive respiratory support: a descriptive study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07603-x

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07603-x

Keywords: dexmedetomidine, pediatric sedation, non-invasive respiratory support, pediatric intensive care, acute respiratory failure, continuous positive airway pressure, high-flow nasal cannula, retrospective study, adverse events, clinical feasibility, Safety, feasibility